Ardsley Advisory Partners’s Pacira BioSciences PCRX Stock Holding History

Ardsley Advisory Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-580,000	Closed	-$16.6M	–	170
2024 Q2	$16.6M	Buy	580,000 +86,600	+18%	+$2.46M	2.44%	8
2024 Q1	$14.4M	Buy	493,400 +191,400	+63%	+$5.88M	2.07%	12
2023 Q4	$10.2M	Sell	302,000 -8,000	-3%	-$234K	1.57%	16
2023 Q3	$9.51M	Buy	+310,000	New	+$11.2M	2.12%	13
2022 Q4	–	Sell	-170,000	Closed	-$9.04M	–	145
2022 Q3	$9.04M	Buy	170,000 +35,000	+26%	+$1.95M	2.02%	15
2022 Q2	$7.87M	Buy	135,000 +35,000	+35%	+$2.29M	1.3%	22
2022 Q1	$7.63M	Buy	+100,000	New	+$6.67M	1.27%	26

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Ardsley Advisory Partners's PCRX Position: Q3 2024 in Review

Ardsley Advisory Partners sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 580,000 shares — an estimated $16.6M sold.

Ardsley Advisory Partners first reported a position in PCRX in Q1 2022 and held it in 7 quarters. The position peaked at $16.6M in Q2 2024. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

Ardsley Advisory Partners reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
Ardsley Advisory Partners sold 580,000 Pacira BioSciences shares in Q3 2024, an estimated $16.6M.
Ardsley Advisory Partners first reported a position in Pacira BioSciences in Q1 2022 and held it in 7 quarters.
Ardsley Advisory Partners's Pacira BioSciences position peaked at $16.6M in Q2 2024.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Ardsley Advisory Partners's 13F filing for Q3 2024, filed 14 Nov 2024.